Month: September 2026

• H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT margin² of 18.8% at CERS:
  • Revenue growth is coming from both segments : companion animal +10.0% and farm animal +6.7% with a strong contribution from our Supercharge platforms (excl. Thyronorm) which increased by around +12% at CERS
  • Solid volume/mix effect of ~+5.4%, completed by price increase of ~+2%
  • Operating margin increased by 0.5ppt compared to H1 2025 driven by a favorable mix effect on the gross margin partially offset by higher operating expenses due to H1/H2 phasing effects.
• Consolidated net income increased by +5.9% to €87.1 million
• Net Debt as of June 2026 up to €196 million compared to €173m as of December 2025 mainly driven by usual working capital requirement seasonality

• 2026 guidance confirmed at the upper end of the range: the strong performance achieved in the first half of the year positions us to target the upper end of our initial revenue growth range (5.5% to 7.5% at CERS) and an adjusted recurring operating income margin of around 17% at CERS

in €m	HY26	HY25	Évolution
Revenues	768.0	738.3	4.0 %
Change at constant exchange rates1			7.4 %
Change at constant exchange rates and scope1			7.4 %
EBIT Adjusted (before amortizations2)	144.2	135.0	6.8%
as a % of revenue	18.8%	18.3%	0.5 p.p
as a % of revenue at constant rates	18.8%	na	na
as a % of revenue at constant exchange rates and scope	18.8%	na	na
Amortization of intangible assets from acquisitions	(5.3)	(2.6)	103.0 %
EBIT Adjusted	138.8	132.4	4.9 %
Non-recurring (expenses) and income	(5.6)	–	–
EBIT	133.3	132.4	0.7 %
Consolidated net income	87.1	82.2	5.9 %
Other financial indicators
Shareholders’ equity – Group share	1 217.1	1 065.1	14.3 %
Net debt3	195.9	172.8	13.4 %
Operating cash flow before interest and taxes4	173.0	164.0	5.5 %

¹Change at constant exchange rates and scope corresponds to organic sales growth, excluding exchange rate variations by calculating the indicator for the current and prior periods using identical exchange rates (the exchange rate used is that of the prior period), and excluding material changes in scope by calculating the indicator for the current period based on the prior period’s consolidation scope. No material scope changes impacted H1 2026 compared to H1 2025. Due to its low materiality, the Thyronorm acquisition has been included in the 2026 organic scope (constant perimeter).

²EBIT Adjusted (before amortizations) corresponds to “recurring operating income before amortization of assets arising from acquisitions”.

³Net debt corresponds to current (€111.5 million) and non-current (€213.5 million) financial liabilities, as well as the lease liability related to the application of IFRS 16 (€42.0 million), less cash and cash equivalents (€171.1 million) as published in the statement of financial position.

⁴Operating cash flow corresponds to the EBIT adjusted before amortizations of asset arising from acquisitions (€144.2 million) restated for depreciation & provisions (€24.5m – amortizations from acquisitions adjusted), non-cash items (€0.9m) and impacts related to disposals (€3.4m).

The financial statements have been audited by the statutory auditors and were reviewed by the Board of Directors on September 17, 2026. The financial statements and the detailed presentation of the annual results are available on the corporate.virbac.com website.

Paul Martingell, Chief Executive Officer statement

“Virbac delivered a strong first half, marked by +7.4% organic growth and an 18.8% operating margin, demonstrating our teams’ ability to turn our commitment to animal health into tangible value. This performance reflects the scaling power of our ‘Supercharge’ platforms and the seamless integration of Thyronorm. Guided by our ‘Growing Together’ 2030 strategy, we are fully on track to achieve our full-year guidance.”

Delivering our 2030 Strategy

In H1 2026, our Supercharge platforms grew by 12% at constant exchange rates (excl. Thyronorm), driven by exceptional performance in our Mobility and Ruminants ranges. The integration of Thyronorm strengthened our Endocrinology Supercharge platform, contributing an additional 3.7 percentage points to overall Supercharge platform growth.

The Group continues to execute its strategic industrial transformation plan. Key ongoing CapEx projects, including the new Vaccines Production Plant, Petfood Facility, Logistics Center, and the Suprelorin Manufacturing Transfer in France, remain fully on track. Concurrently, our global COGS efficiency program, now in its third year, continues to deliver strong results, driving gross margin expansion and effectively offsetting ongoing inflationary pressures.

In line with our strategic roadmap to acquire high-margin, complementary specialty assets, Virbac signed two strategic commercial distribution agreements this year, both featuring defined pathways toward asset or company acquisition:

• Porus-One: Distribution agreement with a purchase option for the Porus-One parent company. This carbon-based uremic toxin binder is complementing our current chronic kidney disease range in cats. Virbac commercialization is planned for 2027.
• Vetcare: Initial distribution agreement transitioning into a Marketing Authorization (MA) acquisition. Featuring a finrozole-based solution for managing heat in female dogs, this asset strengthens Virbac’s reproduction portfolio, with launch planned for 2027.

Half-year 2026 sales by geography

First-half consolidated revenue amounted to €768 million, representing strong growth of +7.4% at constant exchange rates and scope compared to H1 2025. At actual rates first-half growth amounted to 4.0% due to currency headwinds. All regions delivered a solid performance in the first half of the year despite some localised operational challenges.

in €m consolidated not audited	2026	2025	Actual rates	Change at CER2	Change at CERS3
Europe	314	299	5.0 %	6.5 %	6.5 %
North America	103	100	3.1 %	10.1 %	10.1 %
International	351	339	3.4 %	7.5 %	7.5 %
Revenue	768	738	4.0 %	7.4 %	7.4 %

• Europe (+6.5% at CERS): First-half revenue growth was mainly driven by the companion animal segment (+7.2% at CER), primarily fueled by our petfood and endocrinology ranges following the Thyronorm acquisition, alongside our other ‘Supercharge’ platforms. Meanwhile, the farm animal segment grew by +3.1% at CER, led by our cattle vaccine and nutritional portfolios. While H1 revenues for France and Belgium were flat year-over-year due mainly to Q1 supply constraints, our other European markets delivered strong growth. This performance was led by Germany (cattle vaccines) and the UK (endocrinology), and further bolstered by performance in Turkey, which accounted for one-third of our total growth.
• North America (+10.1% at CERS): First-half revenues were primarily driven by strong growth across our ‘Supercharge’ platforms—such as Mobility, Dental, and Ear care—complemented by the endocrinology range from our Thyronorm acquisition. This performance was partially offset by temporary regulatory hurdles in our toll manufacturing business and supply constraints within the farm animal segment. Excluding distributor-level inventory movements (which had a favorable impact on H1 growth) and toll manufacturing activities, underlying organic growth remains around 10%.
• International (+7.5% at CERS): IMEA (India, Middle East & Africa) and Latin America delivered impressive double-digit growth in the first half of the year. This performance was driven by both the companion animal segment—primarily led by petfood, dental, and vaccine ranges—and the farm animal segment, fueled by cattle nutritionals and vaccines. Far East Asia also expanded during the period, driven by strong results in Japan and China. Conversely, the Pacific region faced headwinds due to intense competition in Australia, which was only partially offset by a solid performance in New Zealand.

Half-year 2026 results

EBIT Adjusted (before amortizations²) stood at €144.2 million in HY26 compared to €135.0 million in HY25
The actual margin reached 18.8% in HY26 compared to 18.3% in HY25. The performance in HY26 is explained by an increase in the gross margin (+1ppt) combined with lower R&D expenses in percentage of revenue (+0.8ppt) partially offset by increasing other operating expenses (-1.3ppt):

• The gross margin improvement is primarily attributable to a favorable product mix (including the impact of Thyronorm) supported by a solid volume (~+5.4%) and price evolution (~+2%) as well as a base effect linked to one-off negative impact observed last year.
• Operating expenses (before R&D) increased in percentage of revenue (+1.3ppt) in H1 mainly due to a phasing of expenditures more concentrated in the first half compared to 2025, a few one-off expenses incurred during the first half (incl. costs linked to product discontinuation and third party payment following litigation settlement) partially counterbalanced by R&D, which declined as a percentage of revenue (-0.8 ppt). We expect these items to normalize on a full-year basis.

Consolidated net income €87.1 million, an increase of 5.9% compared to H125

• Amortization charges on intangible assets from acquisitions increased from €2.6 million to €5.3 million, a rise mainly due to the integration of the Thyronorm acquisition completed in December 2025.
• Non-recurring expenses at €5.6 million in H1 2026 composed of (i) an asset impairment of €4.6 million resulting from the strategic discontinuation of a product range, and (ii) an inventory write-down of €1 million linked to exceptional damages. Discussions with insurers regarding potential claims recovery remain ongoing.
• Net financial expense decreased to €3.2 million, compared to €8.5 million in H1 2025, and mainly included foreign exchange loss of €1.5 million, supplemented and the cost of financial debt of €2.2 million.
• Corporate income tax increased to €43.1 million compared to €41.8 million in H1 2025 in line with the level of activity. The effective tax rate remained relatively stable compared to the same period last year.
• Net income – Group share stands at €87.4 million, an increase of 6% compared to the previous year (€82.4 million).

Net debt as of June 2026 increased to €196 million compared to €173 million as of December 2025
This change is mainly explained by the usual seasonal effect on working capital requirements (€79.8 million). Our capex spendings in H1 2026 amounted to €57.3 million essentially linked to our industrial transformation with an additional €5 million payment for an option to acquire a cat specialty product.

Key Events of the period

Virbac announces the appointment of Dr. Éline Maldepuech, Medical Doctor, INSEAD MBA graduate and granddaughter of the Group’s founder, as Censeur of the Board of Directors, effective September 17, 2026.

Guidance 2026 confirmed, at the upper end of the range

While our full-year 2026 guidance remains unchanged, our strong first-half momentum (+7.4% growth) positions us to target the upper end of our revenue growth range of 5.5% to 7.5% at constant rates and scope, with an adjusted recurring operating income expected around 17% at CERS. Cash generation remains unchanged and is expected at approximately +€80m, after Capex spending of around €125m.

In line with our reporting standards, the Thyronorm acquisition is included within the 2026 organic perimeter (constant scope) due to its low level of materiality. Consequently, our guidance accounts for Thyronorm’s contribution to both total revenue (~+1 percentage point of growth) and expected operating income (~+0.5 adjusted Ebit) on a full year basis.

In light of the evolving geopolitical situation in the Middle East, Virbac remains mobilized to effectively assess and manage its operational and financial exposure. Total full-year revenue from countries directly at risk represents less than 0.5% of our global revenue. To date, supply chain disruptions remain limited and manageable within our current stock policy. We are also closely monitoring inflationary trends, including energy costs. Supported by our energy hedging strategy and proactive management, we do not currently anticipate any material impact that would necessitate a revision of our outlook

ANALYSTS’ PRESENTATION – VIRBAC

We will hold an analysts meeting on Friday, September 18 2026 at 2:00 pm (Paris time – CET)

You may also attend the meeting using the webcast (audio + slides) available via the link below.

Information for participants:

Webcast access link: Link

This access link is available on the corporate.virbac.com site, under the heading “Public releases.” This link allows participants to
access the live and/or archived version of the webcast.

You will be able to ask questions via chat (text) directly during the webcast or after watching the replay via the following email
address: finances@virbac.com.

About Virbac – Caring for animals together

At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal pathologies. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together.

More information on corporate.virbac.com

ANNEXES

1.   Income statement of the period

in €k	HY26	HY25	Variance
Net sales	767 951	738 276	4.0%
Raw materials and consumables used	-242 929	-240 856
External expenses	-134 161	-131 601
Personnel expenses	-210 967	-200 677
Taxes and duties	-9 980	-9 741
Depreciation and provisions	-25 557	-28 037
Other operating income and expenses	-158	7 652
Current operating profite before depreciation of assets arising from acquisitions	144 199	135 016	6.8%
Depreciations of intangible assets arising from acquisitions	-5 350	-2 635
Operating profit from ordinary activities	138 849	132 381	4.9%
Other non-recurring income and expenses	-5 570	–
Operating profit	133 279	132 381	0.7%
Financial income and expense	-3 245	-8 492
Profit before tax	130 033	123 889	5.0%
Income tax expense	-43 088	-41 763
Share in earnings – Equity method	172	113
Net income of consolidated entities	87 117	82 239	5.9%
attributable to owners of the parent company	87 373	82 408	6.0%
attributable to non-controlling interests	-255	-169	50.6%

2.   Statement of financial position

in €k	Jun26	Dec25
Goodwill	290 339	356 055
Intangible assets	320 035	231 080
Tangible assets	452 368	424 129
Right of use	40 650	37 623
Other financial assets	52 385	45 123
Share in companies accounted for by the equity method	3 643	3 374
Deferred tax assets	25 508	24 891
Non-current assets	1 184 927	1 122 276
Inventories and work in progress	402 508	378 791
Trade receivables	236 463	201 154
Other financial assets	1 517	3 668
Other receivables	83 828	85 777
Cash and cash equivalents	171 050	122 500
Current assets	895 367	791 891
Assets classified as held for sale	–	–
Assets	2 080 294	1 914 167
Share capital	10 488	10 488
Reserves attributable to the owners of the parent company	1 206 627	1 114 702
Equity attributable to the owners of the parent company	1 217 115	1 125 190
Non-controlling interests	-469	-208
Equity	1 216 646	1 124 982
Deferred tax liabilities	72 790	50 408
Provisions for employee benefits	21 717	21 153
Other provisions	8 233	7 901
Lease obligations	30 146	27 646
Other financial liabilities	213 458	150 410
Other payables	10 204	15 358
Non-current liabilities	356 548	272 876
Other provisions	746	1 371
Trade payables	161 368	170 842
Lease obligations	11 878	11 325
Other financial liabilities	111 518	105 881
Other payables	221 590	226 890
Current liabilities	507 100	516 309
Liabilities	2 080 294	1 914 167

3.   Statement of cash flow

in €k	HY26	HY25
Consolidated result for the period	87 117	82 239
Elimination of share from companies’ profit accounted for by the equity method	-172	-113
Elimination of depreciations & provisions	35 383	31 076
Elimination of deferred tax change	-698	-130
Elimination of gains and losses on disposals	3 405	96
Other income and expenses with no cash impact	4 830	-15 814
Net cash flow	129 865	97 353
Net financial interests paid	2 181	2 761
Income tax accrued for the period	43 793	41 960
Net cash flow before financial interests & income tax	175 838	142 075
Effect of net change in inventories	-16 757	-10 531
Effect of net change in trade receivables	-30 887	-36 972
Effect of net change in trade payables	-5 726	289
Income tax paid	-32 644	-41 275
Effect of net change in other receivables and payables	-37 556	-25 939
Effect of change in working capital requirements	-123 570	-114 428
Net cash flow generated by operating activities	52 268	27 646
Acquisitions of intangible assets	-6 223	-4 719
Acquisitions of tangible assets	-51 094	-49 137
Disposals of intangible and tangible assets	49	52
Change in financial assets	-4 677	-600
Change in debts relative to acquisitions	–	–
Acquisitions of subsidiaries or activities	–	–
Disposals of subsidiaries or activities	–	–
Dividends received	–	–
Net cash flow allocated to investing activities	-61 946	-54 404
Dividends paid to the owners of the parent company	-0	-12 148
Dividends paid to the non-controlling interests	-3	0
Change in treasury shares	–	–
Transactions between the Group and owners of non-controlling interests	–	–
Increase/decrease of capital	–	–
Cash investments	–	–
Debt issuance	85 587	89 633
Repayments of debt	-33 346	-52 703
Repayments of lease obligation	-6 701	-6 591
Net financial interests paid	-2 181	-2 761
Net cash flow from financing activities	43 356	15 430
Change in cash position	33 678	-11 327

4.   Reconciliation tables for alternative performance indicators

4.1.   Net Debt

in €k	Jun26	Dec25
Loans	302 232	248 694
Bank overdrafts	13 616	1 165
Accrued interests not yet matured	48	38
Lease obligation [IFRS16]	42 024	38 971
Employee profit sharing	1 642	1 719
Currency and interest rate derivatives	3 592	809
Other	3 845	3 866
Other financial liabilities	366 999	295 262
Cash	112 617	99 932
Cash equivalents	58 433	22 568
Cash & cash equivalents	171 050	122 500
Net financial debt	195 949	172 762

4.2.   Operating cash flow before interest and taxes

in €k	HY26	HY25
Current operating profit before depreciation of assets arising from acquisitions	144 199	135 016
Elimination of depreciations & provisions	24 462	28 441
Elimination of gains and losses on disposals	3 405	96
Other income & expenses with no cash impact	934	412
Current operating cash flow	173 000	163 964
Other non-current income & expenses	0	0
Operating cash flow	173 000	163 964

Attachment

• Virbac – Press release – FY26 half-year results

 

Nanterre, 17 September 2026

VINCI Autoroutes and VINCI Airports traffic in August 2026

I-      Change in VINCI Autoroutes’ intercity networks traffic

	August	YTD at the end of August (8 months)
	% change 2026/2025	% change 2026/2025
VINCI Autoroutes	-5.6%	-3.2%
Light vehicles	-6.2%	-3.9%
Heavy vehicles	+2.4%	+1.3%

In August, light vehicle traffic declined by -6.2%, reflecting an unfavourable calendar effect* and the sharp rise in fuel prices. Heavy vehicle traffic, meanwhile, rose by +2.4%, benefiting from one additional working day compared with August 2025.

*The main weekend of back-and-forth between “July holidaymakers” and “August holidaymakers” began on Friday, July 31 in 2026 (compared with Friday, August 1 in 2025). In addition, August 15 (a public holiday) fell on a Saturday this year (compared with a Friday in 2025).

II-      Change in VINCI Airports passenger traffic¹

	August	YTD at the end of August (8 months)
	% change 2026/2025	% change 2026/2025
VINCI Airports	-0.8%	-0.1%
Portugal (ANA)	+2.2%	+2.5%
United Kingdom*	+0.0%	-1.1%
France	-0.8%	-1.5%
Serbia	+7.0%	+7.0%
Hungary	+12%	+8.0%
Mexico (OMA)	+4.0%	+3.0%
United States of America	-18%	-11%
Dominican Republic (Aerodom)	+3.0%	+8.6%
Costa Rica	-5.5%	+9.8%
Chile (Nuevo Pudahuel)	-2.7%	-2.5%
Brazil	+0.5%	+4.2%
Japan (Kansai Airports)	-12%	-6.6%
Cambodia (Cambodia Airports)	-16%	-10%
Cabo Verde	+5.8%	+9.4%

¹ Data at 100%, irrespective of percentage held, including airport passenger numbers over the full period
* London Gatwick, Edinburgh and Belfast International airports.

In August, total traffic at VINCI Airports was slightly down (−0.8%), reflecting contrasting trends. Many airports in the network continued to benefit from a good growth momentum, particularly in Portugal, Belgrade, Budapest, Edinburgh, Mexico, the Dominican Republic and Cabo Verde. Conversely, geopolitical disruptions continued to weigh, to varying degrees, on traffic at some airports, in Japan for example.

III-      Change in VINCI Airports commercial movements (ATM)²

	August	YTD at the end of August (8 months)
	% change 2026/2025	% change 2026/2025
VINCI Airports	-1.3%	-1.5%
Portugal (ANA)	+1.5%	+1.3%
United Kingdom*	+0.8%	-0.4%
France	-0.3%	-0.7%
Serbia	+3.3%	+3.7%
Hungary	+4.1%	+4.5%
Mexico (OMA)	+0.1%	+0.1%
United States of America	-11%	-17%
Dominican Republic (Aerodom)	+1.1%	+5.0%
Costa Rica	-0.1%	+19%
Chile (Nuevo Pudahuel)	-2.0%	-2.2%
Brazil	+1.9%	+2.6%
Japan (Kansai Airports)	-9.8%	-8.8%
Cambodia (Cambodia Airports)	-5.7%	-3.4%
Cabo Verde	+1.2%	+10%

² Data at 100%, irrespective of percentage held, including commercial movements over the full period
* London Gatwick, Edinburgh and Belfast International airports.

About VINCI
VINCI is a world leader in concessions, energy solutions and construction, employing 294,000 people in more than 120 countries. We design, finance, build and operate infrastructure and facilities that help improve daily life and mobility for all. Because we believe in all-round performance, above and beyond economic and financial results, we are committed to operating in an environmentally and socially responsible manner. And because our projects are in the public interest, we consider that reaching out to all our stakeholders and engaging in dialogue with them is essential in the conduct of our business activities. VINCI’s ambition is to create long-term value for its customers, shareholders, employees, partners and society in general. www.vinci.com

  

This press release is an official information document of the VINCI Group.

PRESS CONTACT
VINCI Press Department
Tel: +33 (0)1 57 98 62 88
media.relations@vinci.com

 

Attachment

• CP VINCI_traffic August 2026_20260917_VA

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, or in or into Australia, Canada, Japan, South Africa or any other jurisdiction in which it would be unlawful to do so. 
This press release is for information purpose only and does not constitute an offer to sell or a solicitation of an offer to buy any securities and the offer of the Bonds (as defined below) does not constitute an offering (other than to qualified investors) in any jurisdiction, including France.
The Bonds will be offered only to qualified investors which include, for the purpose of this press release, professional clients and eligible counterparties. The securities may not be offered or sold or otherwise made available to retail investors. No key information document under the PRIIPs Regulation or disclosure document required by the FCA Product Disclosure Sourcebook or the CCI Regulations has been or will be prepared.

Soitec launches an offering of bonds settled in cash and/or convertible into new shares and/or exchangeable for existing shares (“ORNANES”) due September 2033 for a nominal amount of €500 million

Bernin (Grenoble), France, on September 17, 2026 – Soitec (the “Company”), a world leader in the design and manufacturing of innovative semiconductor materials, announces the launch, today, of an offering of bonds settled in cash and/or convertible into new shares and/or exchangeable for existing shares of the Company (“ORNANEs”) due September 2033 (the “Bonds”), by way of a placement to qualified investors (within the meaning of the Prospectus Regulation (as defined below)) only in accordance with Article L. 411-2, 1° of the French Code monétaire et financier, for a nominal amount of €500 million (the “Offering”).

Soitec intends to use the net proceeds from the Offering for general corporate purposes, which may include refinancing of existing indebtedness and investments to support the organic growth of the Company.

Main terms of the Bonds

The Bonds will be issued with a denomination of €100,000 each (the “Principal Amount”) and are expected to bear a coupon at a fixed rate between 0.50% and 1.00% per annum from the Issue Date (as defined below), payable annually in arrear on September 25 of each year (or if such date is not a business day, the following business day), and for the first time on September 25, 2027.

The conversion/exchange premium is expected to be set between 50% and 55% above the reference share price, being the placing price of a share in the Concurrent Accelerated Bookbuilding (as defined below).

The Bonds will be issued at 100% of their Principal Amount on September 25, 2026, the expected settlement and delivery date of the Bonds (the “Issue Date”). The settlement of the Concurrent Accelerated Bookbuilding (as defined below) is expected to take place on September 22, 2026.

Unless previously converted, exchanged, redeemed or purchased and cancelled in accordance with the terms and conditions of the Bonds, the Bonds will be redeemed at par on September 25, 2033 (the “Maturity Date”) (or on the following business day if this date is not a business day).

Bondholders will be entitled to require an early redemption of their Bonds on the 5^th anniversary of the Issue Date of the Bonds, at their Principal Amount plus accrued interest.

Bondholders will be granted a conversion/exchange right of the Bonds into new and/or existing shares (the “Conversion/Exchange Right”) which they may exercise (a) from and including the Issue Date (i.e. September 25, 2026) until and including March 25, 2033 only under certain conditions described in the terms and conditions of the Bonds (including, in the event that the Company exercises its right to early redeem the Bonds, in the event of default, in the event of delisting, in the event of a public offer resulting in, or likely to result in, a change of control, or in the event of a parity event), and (b) at any time from and including March 26, 2033 until and including the 30^th business day preceding the Maturity Date, or the relevant early redemption date, as the case may be. The initial conversion/exchange ratio will correspond to the nominal amount of a Bond divided by the initial conversion/exchange price (i.e., the reference share price increased by the conversion/exchange premium).

The ORNANE structure would allow to limit dilution for existing shareholders upon conversion, at the Company’s option. Upon exercise of their Conversion/Exchange Right, Bondholders will receive, at the option of the Company exclusively, an amount payable in cash or an amount payable in cash and in new and/or existing shares of Soitec. The Company will retain the option to deliver new and/or existing shares only. The cash amount that the Company may decide to pay, will be calculated based on the average of volume-weighted average prices of the share over a 20-trading-day period beginning 2 trading days following the Company’s decision to deliver a cash amount to Bondholders, under the conditions described in the terms and conditions of the Bonds.

Shares delivered upon exercise of the Conversion/Exchange Right (if any) will be fully fungible with existing shares of the Company and will carry all rights attached to such shares as from the date of delivery of such shares.

The Bonds may be redeemed prior to the Maturity Date at the discretion of the Company, under certain conditions. In particular, the Bonds may be fully redeemed early at par plus accrued interest at Soitec’s option as from October 16, 2030 until the Maturity Date, if the arithmetic mean of daily products of the VWAP of Soitec’s share price on Euronext Paris and the prevailing conversion/exchange ratio, over a 20-consecutive trading day period chosen by the Company among 40 consecutive trading days preceding the publication of the early redemption notice, exceeds 130% of the Principal Amount of the Bonds. Bondholders will retain the ability to exercise their Conversion/Exchange Right under the conditions set out above.

Upon a Change of Control of the Company or a Delisting of the shares of the Company (as these terms are defined in the terms and conditions of the Bonds), all Bondholders will have an option to request the redemption of the Bonds before the Maturity Date at their Principal Amount plus accrued interest, as set out in the terms and conditions of the Bonds. Bondholders will retain the ability to exercise their Conversion/Exchange Right under the conditions set out above.

Application will be made for the Bonds to be admitted to trading on Euronext Access^TM within 30 calendar days following the Issue Date.

Concurrently, and in order to facilitate hedging for certain subscribers of the Bonds, certain members of the bank syndicate acting as joint bookrunners of the Offering have informed the Company that they are organizing a simultaneous placement of existing shares in Soitec in short sales on behalf of those subscribers, at a placement price to be determined via an accelerated bookbuilding process (the “Concurrent Accelerated Bookbuilding”). Soitec will not receive any proceeds from any sale of shares pursuant to the Concurrent Accelerated Bookbuilding.

Soitec expects to announce the final terms of the Offering and the price of shares sold in the Concurrent Accelerated Bookbuilding tomorrow morning before market opens.

Lock-up

In the context of the Offering, the Company will agree to a lock-up undertaking for a period starting from the announcement of the final terms and conditions of the Bonds and ending 90 calendar days after the Issue Date, subject to certain customary exceptions.

Legal framework of the Offering

The Bonds will be issued by way of a placement to qualified investors only (within the meaning of article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”)), in accordance with Article L. 411-2, 1° of the French monetary and financial code (Code monétaire et financier), as per the authorization granted by the Company’s extraordinary general meeting held on July 22, 2025 (19^th resolution), in France and outside France (excluding in particular the United States of America, Japan, Canada, South Africa or Australia), without an offer to the public (other than to qualified investors) in any country (including France).

Existing shareholders of the Company shall have no preferential subscription rights, and there will be no priority subscription period, in connection with the issuance of the Bonds or the underlying shares of the Company issued upon conversion.

Any offer or sale of shares in the Concurrent Accelerated Bookbuilding will be made (A) in accordance with the provisions of Article L.411-2, 1° of the French monetary and financial code (Code monétaire et financier) and (B) (i) outside the United States in offshore transactions in reliance on Rule 903 of Regulation S under the US Securities Act of 1933 (the “Securities Act”) or (ii) inside the United States to qualified institutional buyers (as defined in Rule 144A under the Securities Act) pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

Dilution

For illustrative purposes, based on a €500 million Offering, a €139.50 reference share price¹ and a 52.5% conversion/exchange premium corresponding to the mid-range of conversion/exchange premium set out above, the potential dilution would represent up to 6.2% of the outstanding share capital², should the Company decide to exclusively deliver new shares upon exercise of the Conversion/Exchange Right.

For illustrative purposes, the below table sets out the potential dilution should Soitec deliver, upon exercise by all Bondholders of their Conversion/Exchange Right, (i) an amount in cash equal to the Principal Amount of the Bonds and (ii) the difference between the Conversion/Exchange Value (as defined in the terms and conditions of the Bonds) and the Principal Amount of the Bonds in shares:

	€212.74 equal to 100% of the initial Conversion/Exchange price of the Bonds	€244.65 equal to 115% of the initial Conversion/Exchange price of the Bonds	€276.56 equal to 130% of the initial Conversion/Exchange price of the Bonds
Dilution2	0.0%2 / 0 new share	0.8%2 / 306,562 new shares	1.5%2 / 542,379 new shares

The above table has been prepared on the basis of the following assumptions:

• a conversion/exchange premium equal to the mid-range of the conversion/exchange premium range set out above;
• a reference share price of €139.50¹, it being noted that the effective reference share price will be set as the placing price of the Concurrent Accelerated Bookbuilding;
• a delivery of new shares only;
• no adjustment of the conversion/exchange ratio.

Available information

The Offering of the Bonds is not subject to a prospectus approved by the French Financial Market Authority (Autorité des Marchés Financiers) (the “AMF”). Detailed information on Soitec, including its business, results, prospects, liquidity position and related risk factors are described in the Company’s universal registration document (Document d’enregistrement universel) filed with the AMF on June 10, 2026 for the financial year ended March 31, 2026, under number D.26-0417, and the Q1 revenue press release for the first quarter ended June 30, 2026 published on July 22, 2026 which are available together with all the press releases and other regulated information about the Company, on Soitec website (www.soitec.com).

Important information

This press release does not constitute or form part of any offer or solicitation to purchase or subscribe for or to sell securities to any person in the United States of America, Australia, Canada, South Africa or Japan or in any jurisdiction to whom or in which such offer is unlawful, and the Offering of the Bonds is not an offer to the public in any jurisdiction, including France, other than to qualified investors within the meaning of the Prospectus Regulation, or an offer to retail investors as such term is defined below.

About Soitec

Soitec (Euronext – Tech Leaders – SBF 120), a world leader in innovative semiconductor materials, has been developing cutting-edge products delivering both technological performance and energy efficiency for over 30 years. From its global headquarters in France, Soitec is expanding internationally with its unique solutions, and generated sales of around 600 million euros in fiscal year 2025-2026. Soitec occupies a key position in the semiconductor value chain, serving three main strategic markets: Mobile Communications, Automotive and Industrial, and Edge and Cloud AI. The company relies on the talent and diversity of nearly 2000 employees, representing 50 different nationalities, working at its sites in Europe, the United States and Asia. Nearly 4,800 patents have been registered by Soitec.

Soitec, SmartSiC™ and Smart Cut™ are registered trademarks of Soitec.

For more information soitec.com and follow us on LinkedIn and X:  @Soitec_Official

Media Relations: media@soitec.com

Investor Relations: investors@soitec.com

Disclaimer

This press release may not be released, published or distributed, directly or indirectly, in or into the United States of America (including its territories and dependencies, any state of the United States and the District of Columbia), or in or into Australia, Canada, South Africa or Japan. The distribution of this press release may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes, should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

No communication or information relating to the offering of the Bonds or the Concurrent Accelerated Bookbuilding may be distributed to the public in a country where a registration or approval is required. No action has been or will be taken in any country in which such registration or approval would be required. The issuance by the Company or the subscription of the Bonds and the Concurrent Accelerated Bookbuilding may be subject to legal and regulatory restrictions in certain jurisdictions; neither the Company, nor the joint bookrunners assume any liability in connection with the breach by any person of such restrictions.

This press release is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) and of the Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). This press release is not an offer to the public other than to qualified investors, or an offer to subscribe or designed to solicit interest for purposes of an offer to the public other than to qualified investors in any jurisdiction, including France.

The Bonds will be offered only by way of an offering in France and outside France (excluding the United States of America, Australia, Canada, South Africa, Japan and any other jurisdiction where a registration process or an approval would be required by applicable laws and regulations), solely to qualified investors as defined in article 2(e) of the Prospectus Regulation and in accordance with Article L. 411-2 1° of the French Monetary and Financial Code (Code monétaire et financier) and paragraph 15 of Schedule 1 to the POATRs. There will be no public offering in any country (including France) in connection with the Bonds, other than to qualified investors. This press release does not constitute a recommendation concerning the issue of the Bonds. The value of the Bonds and the shares of the Company can decrease as well as increase. Potential investors should consult a professional adviser as to the suitability of the Bonds for the person concerned.

PRIIPs Regulation / Prohibition of sales to European Economic Area retail investors

The Bonds are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to, and no action has been undertaken or will be undertaken to offer, sell or otherwise make available any Bonds to any retail investor in the European Economic Area (the “EEA”).

For the purposes of this provision, a “retail investor” means a person who is one (or more) of the following: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended (“MiFID II”); (ii) a customer within the meaning of Directive (EU) 2016/97, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II or (iii) not a qualified investor within the meaning of the Prospectus Regulation. The expression “offer” includes the communication in any form and by any means of sufficient information on the terms of the offer and the Bonds to be offered so as to enable an investor to decide to purchase or subscribe the Bonds. Consequently, no key information document required by Regulation (EU) No 1286/2014, as amended (the “PRIIPs Regulation”) for offering or selling the Bonds or otherwise making them available to retail investors in the EEA has been or will be prepared and therefore offering or selling the Bonds or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

CCI Regulation / Prohibition of sales to UK retail Investors

The Bonds are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise made available to, and no action has been undertaken or will be undertaken to offer, sell or otherwise make available any Bonds to any retail investor in the United Kingdom (“UK”).

For the purposes of this provision, a “retail investor” means a person who is either one (or both) of the following: (i) not a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; or (ii) not a qualified investor as defined in paragraph 15 of Schedule 1 to the POATRs. Consequently, no disclosure document required by the FCA Product Disclosure Sourcebook (“DISC”) for offering, selling or distributing the Bonds or otherwise making them available to retail investors in the UK has been prepared and therefore offering, selling or distributing the Bonds or otherwise making them available to any retail investor in the UK may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.

MIFID II product governance / Professional investors and ECPs only target market – Solely for the purposes of each manufacturer’s product approval process, the target market assessment in respect of the Bonds has led to the conclusion that: (i) the target market for the Bonds is eligible counterparties and professional clients, each as defined in MiFID II; and (ii) all channels for distribution of the Bonds to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Bonds (a “distributor”) should take into consideration the manufacturers’ target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Bonds (by either adopting or refining the manufacturers’ target market assessment) and determining appropriate distribution channels.

UK MIFIR product governance / Professional investors and ECPs only target market – Solely for the purposes of the manufacturer’s product approval process, the target market assessment in respect of the Bonds has led to the conclusion that: (i) the target market for the Bonds is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook (“COBS”), and professional clients, as defined in Regulation (EU) No 600/2014, as amended, as it forms part of UK domestic law by virtue of the EUWA (“UK MiFIR”); and (ii) all channels for distribution of the Bonds to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Bonds (a “distributor”) should take into consideration the manufacturer’s target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the “UK MiFIR Product Governance Rules”) is responsible for undertaking its own target market assessment in respect of the Bonds (by either adopting or refining the manufacturer’s target market assessment) and determining appropriate distribution channels.

France

The Bonds have not been and will not be offered or sold or caused to be offered or sold, directly or indirectly, to the public in France other than to qualified investors. Any offer or sale of the Bonds and distribution of any offering material relating to the Bonds have been and will be made in France only to qualified investors (investisseurs qualifiés), as defined in article 2(e) of the Prospectus Regulation, and in accordance with Article L. 411-2 1° of the French Monetary and Financial Code (Code monétaire et financier).

United Kingdom

This press release is addressed and directed only at persons who (i) are located outside the United Kingdom, or (ii) are “qualified investors” within the meaning of paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 (x) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (y) who fall within Article 49(2) (a) to (d) of the Order or (iii) to whom it may be lawfully communicated (all such persons together with qualified investors in the EEA being referred to as “Relevant Persons”). The Bonds and, as the case may be, the shares to be delivered upon exercise of the conversion/exchange rights (the “Financial Instruments”), are intended only for Relevant Persons and any invitation, offer or agreement related to the subscription, tender, or acquisition of the Financial Instruments may be addressed and/or concluded only with Relevant Persons. All persons other than Relevant Persons must abstain from using or relying on this document and all information contained therein.

This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.

United States of America

This press release may not be released, published or distributed in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia). This press release does not constitute an offer or a solicitation of an offer of securities in the United States. The Bonds and the shares issued or deliverable upon conversion or exchange of the Bonds described in this press release have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state of the United States, and such securities may not be offered, sold, pledged or otherwise transferred in the United States absent registration under the Securities Act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements thereof and applicable state or local securities laws. The Company does not intend to make a public offer of its securities in the United States.

Australia, Canada, South Africa and Japan

The Bonds may not and will not be offered, sold or purchased in Australia, Canada, South Africa or Japan. The information contained in this press release does not constitute an offer of securities for sale in Australia, Canada, South Africa or Japan.

The distribution of this press release in certain countries may constitute a breach of applicable law.

---

¹ Closing price of Soitec’s share on Euronext Paris on September 16, 2026
² Based on 35,814,320 shares in Soitec’s share capital

Attachment

• Soitec Offering of bonds ORNANES_Launch PR_ENG

Foresight Technology VCT plc
LEI: 21380013CXOR8N6OD977

17 SEPTEMBER 2026
Board Changes

In accordance with UKLR 6.4.6R, the Board of Foresight Technology VCT plc (the “Company”) is delighted to announce the appointment of Michael Gray as a non-executive director of the Company with effect from 17 September 2026.

Michael has extensive experience in funds, banking and other capital markets. He was most recently the regional managing director, corporate banking for RBS International with responsibility for The Royal Bank of Scotland’s Corporate Banking Business in the Crown Dependencies and British Overseas Territories. In a career spanning 31 years with The Royal Bank of Scotland Group plc, Michael has undertaken a variety of roles including that of auditor and has extensive general management and lending experience across a number of industries.

In accordance with UKLR 6.4.8R, Michael Gray’s current and previous directorships in the past five years are disclosed below. Michael does not hold any shares in the Company at the date of his appointment to the Board.

Current Directorships/Partnerships	Former Directorships/Partnerships (past five years)
J-Star Jersey Company Limited	Foresight Enterprise VCT plc
MMG Consulting Limited	Team plc
MMG Investments Limited	JTC plc
Triton Investment Management Limited	GCP Infrastructure Investments Ltd
JST Company Limited
EPE Special Opportunities Limited
ESO 1 Ltd
ESO 2 Ltd
Evelyn Partners International Limited

The Board has considered Michael’s independence, including the fact that he was until recently a director of Foresight Enterprise VCT plc, a company managed by the Company’s manager, Foresight Group LLP. Having done so, the Board considers Michael to be independent in character and judgement and independent of the manager.

Michael Gray’s appointment forms part of the Board’s succession planning following Tim Dowlen’s retirement from the Board at the conclusion of the Company’s AGM on 17 September 2026.

The Board would like to take this opportunity to thank Tim for his commitment and valuable contribution during his tenure.

Michael Gray will be appointed as a member of the Audit, Management Engagement and Remuneration, and Nomination Committees following his appointment.

There are no other matters requiring disclosure in relation to Michael’s appointment under UK Listing Rule 6.4.8R (1) – (6) inclusive.

For further information, please contact:

Company Secretary
Foresight Group LLP
Contact: Stephen Thayer Tel: 0203 667 8100

BASSETT, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) — Bassett Furniture Industries, Inc. (Nasdaq: BSET) today announced it will host a conference call with management on Thursday, October 1, 2026, at 9:00 a.m. ET to discuss its third quarter 2026 financial results. The Company plans to issue its earnings release after the market closes on Wednesday, September 30, 2026. Rob Spilman, Chairman and CEO will host the call, along with Mike Daniel, Senior Vice President and CFO.

The public is invited to listen to the conference call by webcast, accessible through the Company’s investor relations website, https://investors.bassettfurniture.com, or they can listen to the conference call via https://edge.media-server.com/mmc/p/rre7zxb2/. The conference call will be archived for replay on the Company’s investor site.

About Bassett Furniture Industries, Inc.

Bassett Furniture Industries, Inc. (NASDAQ: BSET) is a leading provider of high-quality home furnishings. The Company’s network of 87 company- and licensee-owned Bassett Home Furnishings stores accounts for approximately 60% of its wholesale business. The Bassett Home Furnishings stores feature the latest on-trend furniture styles, showcase the Company’s capabilities in custom furniture design and manufacturing, provide free in-home design visits, and display coordinated decorating accessories in a professional and friendly environment. Bassett also has a significant traditional wholesale business with more than 1000 open market accounts. Most of the open market sales are through Bassett Design Centers and Bassett Custom Studios which function as a store within a multi-line store showcasing the Company’s custom furniture capabilities. The wholesale business, including the Lane Venture outdoor brand, also services general furniture stores and a growing number of interior design firms. Bassett products are also directly available to consumers at www.bassettfurniture.com. (BSET-E)

Contacts:
J. Michael Daniel
Senior Vice President and 
Chief Financial Officer
(276) 629-6614 – Investors 
mdaniel@bassettfurniture.com

Peter D. Morrison
Vice President of Communications
(276) 629-6450 – Media

POCASSET, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) —

WHAT: HII (NYSE: HII), a global leader in autonomous unmanned maritime systems, will host a ribbon-cutting ceremony celebrating the expansion of its unmanned maritime systems production facility in Pocasset, Massachusetts.

The new 10,000-square-foot expansion will increase HII’s capacity to produce and support autonomous maritime systems for the U.S. Navy, allies and partners. The facility supports HII’s REMUS unmanned underwater vehicles, ROMULUS unmanned surface vehicles and Odyssey advanced autonomy solutions.

Media will have the opportunity to tour the expanded production facility, see the REMUS UUV production line and speak with HII leaders about increased production capacity and the integration of unmanned systems into future fleet operations.

HII has delivered more than 750 REMUS vehicles to customers in more than 30 countries, including 14 NATO members. The Pocasset facility is currently producing REMUS UUVs for multiple customers, including the U.S. Navy’s Lionfish small unmanned undersea vehicle.

Who:
	Duane Fotheringham, president of the Unmanned Systems group in HII’s Mission Technologies division.
	U.S. Rep. Bill Keating (D-MA-09)
When:
	Monday, Sept. 21, 2026
	10 a.m. Eastern Time
Where:
	HII Unmanned Production Facility
	16 Jonathan Bourne Drive
	Pocasset, Massachusetts
RSVP:
	gregory.j.mccarthy@hii-co.com

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. Learn more:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Greg McCarthy
(202) 264-7126
gregory.j.mccarthy@hii-co.com